Karen O&#x;Leary
Karen O&#x;Leary
Karen O&#x;Leary
Karen O&#x;Leary
Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial [0.03%]
出版更正：针对复发/难治性T-细胞急性淋巴细胞白血病的同种异体CD5特异性CAR-T疗法I期临床试验
Jing Pan,Yue Tan,Lingling Shan et al.
Jing Pan et al.
Published Erratum
Nature medicine. 2024 Oct 16. DOI:10.1038/s41591-024-03348-1 2024
James M Hillis,Kenneth Payne
James M Hillis
Soshana P Svendsen,Clive N Svendsen
Soshana P Svendsen
Cell therapies for neurological disorders are entering the clinic and present unique challenges and opportunities compared with conventional medicines. They have the potential to replace damaged nervous tissue and integrate into the brain o...
Karen O&#x;Leary
Karen O&#x;Leary
Faiez Zannad,Otavio Berwanger,Stefano Corda et al.
Faiez Zannad et al.
Cardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, w...
Amiya Bhatia,Anja Zinke-Allmang,Clare Ahabwe Bangirana et al.
Amiya Bhatia et al.